Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.30
Bid: 1.30
Ask: 1.33
Change: 0.00 (0.00%)
Spread: 0.03 (2.308%)
Open: 1.30
High: 0.00
Low: 0.00
Prev. Close: 1.30
RTW Live PriceLast checked at -
RTW Venture is an Investment Trust

To achieve positive absolute performance and superior long-term capital appreciation, with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

25 Jun 2020 18:08

RNS Number : 1441R
RTW Venture Fund Limited
25 June 2020
 

25 June 2020

RTW VENTURE FUND LIMITED

 (the "Company")

 

Results of the Annual General Meeting ("AGM")

 

The Company is pleased to announce that, at the first AGM held at 14.00 BST today, 25 June 2020, each of the Resolutions were duly passed without amendment.

 

The details of each resolution are as follows:

 

ORDINARY RESOLUTIONS

 

Resolution 1

IT WAS RESOLVED to receive and consider the Audited Financial Statements, the Directors' report, and the auditor's report for the financial year ended 31 December 2019.

 

For (including discretionary)

83,541,534 votes

Against

0 votes

Withheld

0 votes

Resolution 2

IT WAS RESOLVED to approve the Directors' remuneration for the financial year ended 31 December 2019 as provided in the Directors' report.

 

For (including discretionary)

83,467,433 votes

Against

74,101 votes

Withheld

0 votes

Resolution 3¹

IT WAS RESOLVED to elect William Simpson as a Director of the Company.

 

For (including discretionary)

83,467,433 votes

Against

0 votes

Withheld

74,101 votes

 

Resolution 4¹

IT WAS RESOLVED to elect Paul Le Page as a Director of the Company.

 

For (including discretionary)

83,467,433 votes

Against

0 votes

Withheld

74,101 votes

 

Resolution 5¹

IT WAS RESOLVED to elect Bill Scott as a Director of the Company.

 

For (including discretionary)

83,467,433 votes

Against

0 votes

Withheld

74,101 votes

 

 

 

Resolution 6¹

IT WAS RESOLVED to elect Stephanie Sirota as a Director of the Company.

 

For (including discretionary)

83,541,534 votes

Against

0 votes

Withheld

0 votes

 

Resolution 7

IT WAS RESOLVED to re-appoint KPMG Channel Islands Limited and KPMG LLP as Auditors of the Company.

 

For (including discretionary)

83,541,534 votes

Against

0 votes

Withheld

0 votes

 

Resolution 8

IT WAS RESOLVED to authorise the Board of Directors to determine the remuneration of the Auditors.

 

For (including discretionary)

83,541,534 votes

Against

0 votes

Withheld

0 votes

 

Details of those resolutions passed, which were not ordinary business of the AGM, follow:-

 

Resolution

Votes For (including discretionary)

Votes Against

Votes Withheld*

9 - Special

83,541,534 votes

0 votes

0 votes

 

*A vote withheld is not a vote in law and is therefore not counted towards the proportion of votes "for" or "against" the Resolution.

 

Resolution 9

That the Company be and is hereby authorised, in accordance with section 315 of the Companies (Guernsey) Law, 2008, as amended (the "Companies Law"), subject to the Listing Rules made by the United Kingdom Financial Conduct Authority and all other applicable legislation and regulations, to make market acquisitions (within the meaning of section 316 of the Companies Law) of its own Ordinary Shares (as defined in the Company's Articles) which may be cancelled or held as treasury shares, provided that:

i. the maximum number of Ordinary Shares authorised to be purchased under this authority shall be 26,650,546 Ordinary Shares (being 14.99 per cent. of the Ordinary Shares in issue as at the Latest Practicable Date, excluding any treasury shares);

ii. the minimum price (exclusive of expenses) which may be paid for an Ordinary Share is US$0.01;

iii. the maximum price (exclusive of expenses) which may be paid for an Ordinary Share shall be not more than an amount equal to the higher of (a) 5 per cent. above the average mid-market value of the Ordinary Shares on the regulated market where the repurchase is carried out for the five Business Days (as defined in the Company's Articles) prior to the day the purchase is made and (b) the higher of (i) the price of the last independent trade and (ii) the highest current independent bid price, in each case on the regulated market where the purchase is carried out; and

such authority to expire on the date which is 15 months from the date of passing of this resolution or, if earlier, at the end of the Annual General Meeting of the Company to be held in 2021 (unless previously renewed, revoked or varied by the Company by special resolution), save that the Company may make a contract to acquire Ordinary Shares under this authority before its expiry which will or may be executed wholly or partly after its expiration and the Company may make an acquisition of Ordinary Shares pursuant to such a contract.

 

Resolution 10

Resolution 10 had been withdrawn with the unanimous consent of the AGM.

 

Responses to investor's questions will be posted on the Company's website after the AGM.

 

¹ The Company notes that the voting rights adjustments under Article 23 were used in respect of resolutions 3, 4, 5 and 6, but this did not affect the outcome of the shareholder vote.

 

For further information

 

RTW Investments, LP +1 (646) 343 9280Stephanie Sirota, Chief Business Officer

Alexandra Taracanova, PhD, Director of Investor Relations

Julia Enright, Business Development Associate

 

Ocorian (Company Secretary) +44 (0)1481 742 642Kevin Smith

 

J.P. Morgan Cazenove +44 (0)20 7742 4000

William Simmonds

Oliver Kenyon

James Bouverat (Sales)

 

Barclays +44 (0)20 7623 2323

Tom Swerling

Andrew Tusa

Alwyn Clarke

Ryan McCarthy

 

About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading US healthcare investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the RTW website at www.rtwfunds.com for more information.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGSEMFWIESSESM
Date   Source Headline
30th Mar 20234:35 pmRNSPrice Monitoring Extension
29th Mar 202310:47 amRNSPortfolio Company Update: Strategic Financing
16th Mar 20234:00 pmRNSDirector Declaration
14th Mar 20237:00 amRNSMonthly Valuation Update
13th Mar 20233:20 pmRNSUpdate re Silicon Valley Bank exposure
1st Mar 20232:45 pmRNSNew Investment in Cargo Therapeutics
1st Mar 202310:00 amRNSNew Investment in Oricell Therapeutics
14th Feb 20237:00 amRNSMonthly Valuation Update
13th Feb 20234:51 pmRNSPortfolio Company Update
26th Jan 202311:32 amRNSQuotedData's Weekly News & Interview
25th Jan 20237:00 amRNSQuarterly Update
20th Jan 20234:29 pmRNSUpdate research from QuotedData
16th Jan 20237:00 amRNSNet Asset Value(s)
22nd Dec 20224:23 pmRNSDirector/PDMR Shareholding
19th Dec 202211:17 amRNSResult of General Meeting
14th Dec 20227:00 amRNSNet Asset Value(s)
13th Dec 202210:01 amRNSEdison issues flash on RTW Venture Fund (RTW)
8th Dec 20225:57 pmRNSMaterial Update from Portfolio Company
7th Dec 20221:00 pmRNSNew Investment in Apogee Therapeutics
1st Dec 20227:00 amRNSPublication of Circular & Convening of EGM
30th Nov 20222:00 pmRNSDirector/PDMR Shareholding
28th Nov 20227:00 amRNSChange of status for US federal tax - PTP to PFIC
14th Nov 20227:00 amRNSNet Asset Value(s)
4th Nov 20224:04 pmRNSDirector/PDMR Shareholding
1st Nov 20225:07 pmRNSDirector/PDMR Shareholding
25th Oct 20227:00 amRNSQuarterly Update
20th Oct 20227:00 amRNSEdison issues review on RTW Venture Fund (RTW)
14th Oct 20227:00 amRNSNet Asset Value(s)
22nd Sep 20227:00 amRNSDirector/PDMR Shareholding
16th Sep 20227:00 amRNSPortfolio Company Update: Third Harmonic Bio IPO
15th Sep 20227:30 amRNSNet Asset Value(s)
15th Sep 20227:00 amRNSHalf-year Report
17th Aug 202212:00 pmRNSNotice of Interim Report
12th Aug 20227:00 amRNSNet Asset Value(s)
26th Jul 20227:00 amRNSQuarterly Update
19th Jul 20227:55 amRNSAdditional Investment in Portfolio Company
15th Jul 20227:00 amRNSNet Asset Value(s)
6th Jul 20227:00 amRNSPortfolio Company Transaction Update
21st Jun 20225:33 pmRNSResult of AGM
13th Jun 20227:00 amRNSNet Asset Value(s)
17th May 20227:00 amRNSNotice of AGM
13th May 20227:00 amRNSNet Asset Value(s)
28th Apr 20227:00 amRNSQuarterly Update
14th Apr 20227:05 amRNSNew Investment
14th Apr 20227:00 amRNSNet Asset Value(s)
4th Apr 20224:23 pmRNSDirector/PDMR Shareholding
4th Apr 20224:22 pmRNSDirector/PDMR Shareholding
31st Mar 20227:00 amRNSAnnual Financial Report
14th Mar 20227:00 amRNSNet Asset Value(s)
7th Mar 20227:00 amRNSNotice of Annual Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.